Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial of Efficacy and Safety of Subetta in the Treatment of Impaired Glucose Tolerance

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Outpatients aged 18 to 70 years.~2. Impaired glucose tolerance (plasma glucose from 7.8 to 11.0 mmol / L 2 hours after a 75 g oral glucose consumption during an oral glucose tolerance test, while fasting plasma glucose \<7.0 mmol / L).~3. HbA1c is 5.7-6.4%.~4. The body mass index is 25.0-39.9 kg / m\^2.~5. Consent to use reliable contraceptive methods during the study (for men and women with reproductive potential).~6. The presence of the signed informed consent form to participate in the clinical trial.~Exclusion Criteria:~1. Type 1 or type 2 diabetes.~2. Use of any medications indicated in the section Prohibited concomitant medications.~3. Acute or exacerbation / decompensation of a chronic disease of any etiology at the time of the examination or during the previous week.~4. Uncontrolled arterial hypertension with blood pressure: systolic blood pressure \> 160 mm Hg and/or diastolic blood pressure \> 110 mm Hg.~5. Acute coronary syndrome, myocardial infarction, acute impairment of cerebral circulation during the previous 6 months prior to enrollment.~6. Unstable or life-threatening arrhythmia during the previous 3 months prior to enrollment.~7. Acute and chronic heart failure with functional class III or IV (according to the classification of the New York Heart Association, 1964).~8. Respiratory failure.~9. Chronic kidney disease (classes C3-5 A3).~10. Hepatic insufficiency (class C according to Child-Pugh).~11. Presence or suspicion of oncology disease.~12. The presence of an allergy / hypersensitivity to any component of the medication administered during the treatment.~13. Alcohol consumption \> 2 alcohol units for males and \> 1 alcohol unit for females per day.~14. Mental illness or drug abuse in anamnesis.~15. Bariatric surgery in anamnesis, any surgery for 3 months before enrollment.~16. Pregnancy, breast-feeding; childbirth less than 3 months before enrollment.~17. Participation in other clinical trials for 3 months before enrollment in this study.~18. Patients who are related to any of the on-site research personnel directly involved in the conduct of the trial or are an immediate relative of the study investigator. 'Immediate relative' means husband, wife, parent, son, daughter, brother, or sister (regardless of whether they are natural or adopted).~19. Patients who work for MATERIA MEDICA HOLDING (i.e. the company's employees, temporary contract workers, appointed officials responsible for carrying out the research or immediate relatives of the aforementioned).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Subetta (Type: EXPERIMENTAL): Tablet for oral use. 2 tablets twice daily. The tablets should be held in mouth until completely dissolved 15 min prior to meal.
- Placebo (Type: PLACEBO_COMPARATOR): Tablet for oral use. 2 tablets twice daily. The tablets should be held in mouth until completely dissolved 15 min prior to meal.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete